Loading…
Financial toxicity in allogeneic haematopoietic stem cell transplant patients from a social determinants of health perspective
Financial toxicity (FT) refers to the subjective perception of financial distress resulting from objective economic strain due to illness, exerting a detrimental influence on health outcomes. This study aimed to describe FT among allogeneic haematopoietic stem cell transplant (allo-HSCT) recipients...
Saved in:
Published in: | European journal of oncology nursing : the official journal of European Oncology Nursing Society 2024-06, Vol.70, p.102584, Article 102584 |
---|---|
Main Authors: | , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Financial toxicity (FT) refers to the subjective perception of financial distress resulting from objective economic strain due to illness, exerting a detrimental influence on health outcomes. This study aimed to describe FT among allogeneic haematopoietic stem cell transplant (allo-HSCT) recipients within a public health framework, employing a social determinants of health approach.
A multi-centre cross-sectional study involving adult allo-HSCT patients was conducted across three public hospitals in Madrid. FT was assessed using a validated COST scale (range 0–44; lower scores indicating higher FT). Patient-administered paper/online questionnaires were utilized to collect data on sociodemographic, socioeconomic, clinical, and healthcare access variables. Descriptive, non-parametric univariate statistical analysis and multiple linear regression models were performed.
Sixty-six patients, with a mean age: 52.5 years (SD: 11.5), 50% women, 28.7% displaced to Madrid for HSCT, and 71.4% lacking financial support were included. The median FT score was 20 points (IQR 12–27.25). Independent factors associated with higher FT included being females (Coef = −3.26; p = 0.079), perceived income loss after HSCT (Coef = −6.81; p 2500 € (Coef = 15.75; p |
---|---|
ISSN: | 1462-3889 1532-2122 1532-2122 |
DOI: | 10.1016/j.ejon.2024.102584 |